In this issue:
Tocilizumab in patients with severe COVID-19
Glucocorticoids with or without tocilizumab vs supportive care only in patients with COVID-19-associated cytokine storm syndrome
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation
Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease
Tapering towards DMARD-free remission in established RA
Six-month flare risk after discontinuing long-term methotrexate in RA with low disease activity
Rituximab to induce remission after relapse in AAV
Reasons for biologic and targeted synthetic DMARD cessation and persistence of second-line treatment in RA
Association of pain centralisation and patient-reported pain in active RA
Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases
Please login below to download this issue (PDF)